Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Category Primary study
JournalBlood
Year 2023
This article has no abstract
Epistemonikos ID: c8eb528d74faf2d62848d37de9c841633d160ead
First added on: Apr 29, 2024